W. Ageno, A. S. Gallus, A. Wittkowsky, M. Crowther, E. M. Hylek et al., Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, Chest, vol.141, pp.44-88, 2012.

D. S. Budnitz, M. C. Lovergrove, N. Shehab, and C. L. Richards, Emergency hospitalizations for adverse drug events in older Americans, N Engl J Med, vol.365, pp.2002-2014, 2011.

D. M. Witt, T. Delate, and E. M. Hylek, Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes, Thromb Res, vol.132, pp.770-775, 2013.

M. R. Patel, K. W. Mahaffey, and J. Garg, Rivaroxaban versus warfarin in non valvular atrial fibrillation, N Engl J Med, vol.365, pp.883-91, 2011.

S. J. Connolly, M. D. Ezekowitz, and S. Yusuf, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, vol.361, pp.1139-51, 2009.

C. B. Granger, J. H. Alexander, and J. Mcmurray, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, vol.365, pp.981-92, 2011.

T. B. Larsen, L. H. Rasmussen, and F. Skjoth, Efficacy and safety of dabigatran etexilate and warfarin in "real world" patients with atrial fibrillation: A prospective nationwide cohort, J Am Coll Cardiol, vol.61, pp.2264-73, 2013.

T. B. Larsen, A. Gorst-rasmissen, L. H. Rasmussen, F. Skjoth, M. Rosenzweig et al., Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation, Am J Med, vol.127, pp.650-656, 2014.

M. Avgil-tsadok, C. A. Jackevicius, and V. Essebag, Dabigatran use in elderly patients with atrial fibrillation, Thromb Haemost, vol.115, pp.152-160, 2016.

L. G. Bengtson, P. L. Lutsey, L. Y. Chen, R. F. Maclehose, and A. Alonso, Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation, J Cardiol, vol.69, pp.868-76, 2017.

Y. H. Chan, K. C. Yen, and L. C. See, bleeding, and mortality risks of dabigatran in Asians with nonvalvular atrial fibrillation, Stroke, vol.47, pp.441-450, 2016.

D. J. Graham, M. E. Reichman, and M. Wernecke, Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation, Circulation, vol.131, pp.157-64, 2015.

S. Halvorsen, W. Ghanima, F. Tvete, and I. , A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants, Eur Heart J Cardiovasc Pharmacother, vol.3, pp.28-36, 2017.

P. S. Nishtala, D. Gnjidic, H. A. Jamieson, H. C. Hanger, C. Kaluarachchi et al., Real-world' haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand, Int J Cardiol, vol.203, pp.746-52, 2016.

J. D. Seeger, K. Bykov, D. B. Bartels, K. Huybrechts, K. Zint et al., Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation, Thromb Haemost, vol.114, pp.1277-89, 2015.

L. Staerk, E. L. Fosbol, and G. Lip, Ischaemic and haemorrhagic stroke associated with non-vitamin k antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: A nationwide cohort study, Eur Heart J, vol.38, pp.907-922, 2017.

T. C. Villines, J. Schnee, and K. Fraeman, A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system, Thromb Haemost, vol.114, pp.1290-1298, 2015.

X. Yao, N. S. Abraham, and L. R. Sangaralingham, Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation, J Am Heart Assoc, vol.5, p.3725, 2016.

Y. H. Chan, C. T. Kuo, and Y. H. Yeh, Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in asians with nonvalvular atrial fibrillation, J Am Coll Cardiol, vol.68, pp.1389-1401, 2016.

C. I. Coleman, M. Antz, and K. Bowrin, Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the united states: The REVISIT-US study, Curr Med Res Opin, vol.32, issue.12, pp.2047-53, 2016.

V. Sarrazin, M. S. Jones, M. Mazur, A. Chrischilles, E. Cram et al., Bleeding rates in veterans affairs patients with atrial fibrillation who switch from warfarin to dabigatran, Am J Med, vol.127, pp.1179-85, 2014.

F. Laliberté, M. Cloutier, and W. W. Nelson, Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients, Curr Med Res Opin, vol.30, pp.1317-1342, 2014.

N. S. Abraham, S. Singh, G. C. Alexander, H. Heien, L. R. Haas et al., Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study, BMJ, vol.350, p.1857, 2015.

I. Hernandez, S. H. Baik, A. Pinera, and Y. Zhang, Risk of bleeding with dabigatran in atrial fibrillation, JAMA Intern Med, vol.175, pp.18-24, 2015.

H. Y. Chang, M. Zhou, W. Tang, G. C. Alexander, and S. Singh, Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study, BMJ, vol.350, p.1585, 2015.

J. C. Lauffenburger, J. F. Farley, A. K. Gehi, D. H. Rhoney, M. A. Brookhart et al., Effectiveness and safety of dabigatran and warfarin in real-world us patients with non-valvular atrial fibrillation: A retrospective cohort study, J Am Heart Assoc, vol.4, p.1798, 2015.

G. Lip, X. Pan, and S. Kamble, Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: A "real-world" observational study in the united states, Int J Clin Pract, vol.70, pp.752-63, 2016.

J. Carmo, F. M. Costa, J. Ferreira, and M. Mendes, Dabigatran in real-world atrial fibrillation

, Meta-analysis of observational comparison studies with vitamin K antagonists, Thromb Haemost, vol.116, pp.754-763, 2016.

E. R. Weeda, C. M. White, W. F. Peacock, and C. I. Coleman, Rates of major bleeding with rivaroxaban in real-world studies of nonvalvular atrial fibrillation patients: a meta-analysis, Curr Med Res Opin, vol.32, pp.1117-1137, 2016.

G. Ntaios, V. Papavasileiou, K. Makaritsis, K. Vemmos, P. Michel et al., Real-world setting comparison of nonvitamin-k antagonist oral anticoagulants versus vitamin-k antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis, Stroke, vol.48, pp.2494-2503, 2017.

M. Proietti, I. Romanazzi, G. F. Romiti, A. Farcomeni, and G. Lip, Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis, Stroke, vol.49, pp.98-106, 2018.

Y. Vinogradova, C. Coupland, T. Hill, and J. Hippisley-cox, Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care, BMJ, vol.362, p.2505, 2018.

E. Oger, M. A. Botrel, C. Juchault, and J. Bouget, Sensitivity and specificity of an algorithm based on medico-administrative data to identify hospitalized patients with major bleeding presenting to an emergency department, BMC Med Res Methodol, vol.19, issue.1, p.194, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02363490

J. Bouget, F. Balusson, and L. M. Scailteux, Major bleeding with antithrombotic agents: a 2012-2015 study using the French nationwide Health Insurance Database (SNIIRAM) linked to emergency departments records within five areas. Rationale and design of SACHA study, Fundam Clin Pharmacol, vol.33, issue.4, pp.443-462, 2019.

S. Kaatz, D. Ahmad, and A. C. Spyropoulos, Schulman S for the Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH, J Thromb Haemost, vol.13, pp.2119-2145, 2015.

R. Pisters, D. A. Lane, R. Nieuwlaat, C. B. De-vos, H. J. Crijns et al., A novel user friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey, Chest, vol.138, pp.1093-1100, 2010.

A. Bannay, C. Chaignot, and P. O. Blotière, The best use of the charlson comorbidity index with electronic health care database to predict mortality, Med Care, vol.54, pp.188-94, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01817541

P. C. Austin, An introduction to propensity score methods for reducing the effects of confounding in observational studies, Multivariate Behav Res, vol.46, pp.399-424, 2011.

S. R. Cole and M. A. Hernán, Constructing inverse probability weights for marginal structural models, Am J Epidemiol, vol.168, pp.656-64, 2008.

D. G. Altman and P. K. Andersen, Calculating the number needed to treat for trials where the outcome is time to an event, BMJ, vol.319, pp.1492-1497, 1999.

G. Maura, P. O. Blotière, K. Bouillon, C. Billionnet, P. Ricordeau et al., Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists : a French nationwide propensity-matched cohort study, Circulation, vol.132, pp.1252-1260, 2015.

A. Ruigómez, G. Brobert, K. Suzart-woischnik, and L. A. García-rodríguez, Ascertainment and validation of major bleeding events in a primary care database, Pharmacoepidemiol Drug Saf, 2018.

T. B. Larsen, F. Skjoth, P. B. Nielsen, J. N. Kjaeldgaard, and G. Lip, Comparative effectiveness and safety of non-vitamin k antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: Propensity weighted nationwide cohort study, BMJ, vol.353, p.3189, 2016.

P. B. Nielsen, F. Skjøth, M. Søgaard, J. N. Kjaeldgaard, G. Lip et al., Effectiveness and safety of low-dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study, BMJ, vol.356, p.510, 2017.

Y. He, I. C. Wong, X. Li, and S. Anand, The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies, Br J Clin Pharmacol, vol.82, pp.285-300, 2016.

D. Caldeira, M. Barra, and A. Ferreira, Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants, Aliment Pharmacol Ther, vol.42, pp.1239-1288, 2015.

L. Loffredo, L. Perri, and F. Violi, Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: a meta-analysis of interventional trials, Dig Liver Di, vol.47, pp.429-460, 2015.

. I490x, , vol.658, p.694

. Demp001, , p.3

. Venous-thromboembolism-i26x, , p.223

. Dhqh003, , p.1

Y. T840x, , vol.470, p.966

. Bfka001, , p.9